Un estudio de fase III de HMPL-760 en combinación con R-GemOx frente a placebo en combinación con R-GemOx en DLBCL recidivante/refractario
Un Estudio Aleatorizado de Fase III, Doble Ciego, Controlado Positivo para Evaluar la Eficacia, Seguridad y Farmacocinética de HMPL-760 en Combinación con R-GemOx Frente a Placebo en Combinación con R-GemOx en Pacientes con Linfoma Difuso de Células B Grandes (DLBCL) Recaído/Refractario
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Dongmei Chen, CPL
- Número de teléfono: 86-21-20671794
- Correo electrónico: dongmeic@hutch-med.com
Ubicaciones de estudio
-
-
-
Baoding, Porcelana
- Reclutamiento
- Baoding NO.1 Central Hospital
-
Contacto:
- Haiying Yao
- Número de teléfono: 18617789030
- Correo electrónico: haiyingyaobd@163.com
-
Investigador principal:
- Haiying Yao
-
Beijing, Porcelana
- Reclutamiento
- Beijing GoBroad Hospital
-
Investigador principal:
- Kai Hu
-
Contacto:
- Kai Hu
- Número de teléfono: 15010390336
- Correo electrónico: HK13610956245@163.com
-
Beijing, Porcelana
- Reclutamiento
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
Investigador principal:
- Liang Wang
-
Contacto:
- Liang Wang
- Número de teléfono: 15001108693
- Correo electrónico: wangliangtrhos@126.com
-
Bengbu, Porcelana
- Reclutamiento
- The First Affiliated Hospital of Bengbu Medical College
-
Contacto:
- Yanli Yang
- Número de teléfono: 13855249678
- Correo electrónico: Yangyanli0702@126.com
-
Investigador principal:
- Yanli Yang
-
Changchun, Porcelana
- Reclutamiento
- The First Hospital of Jilin University
-
Investigador principal:
- Ou Bai
-
Contacto:
- Ou Bai
- Número de teléfono: 13039046656
- Correo electrónico: lbl2054@163.com
-
Changsha, Porcelana
- Reclutamiento
- Hunan Cancer Hospital
-
Investigador principal:
- Hui Zhou
-
Contacto:
- Hui Zhou
- Número de teléfono: 13975879796
- Correo electrónico: zhouhui9403@126.com
-
Changsha, Porcelana
- Reclutamiento
- The Second Xiangya Hospital of Central South University
-
Investigador principal:
- Hongling Peng
-
Contacto:
- Hongling Peng
- Número de teléfono: 18900766137
- Correo electrónico: Penghongling@aliyun.com
-
Changsha, Porcelana
- Reclutamiento
- People's Hospital of Hunan Province
-
Contacto:
- Can Liu
- Número de teléfono: 137 8728 5260
- Correo electrónico: 617170469@qq.com
-
Investigador principal:
- Can Liu
-
Chengdu, Porcelana
- Reclutamiento
- West China Hospital of Sichuan University
-
Investigador principal:
- Liqun Zou
-
Contacto:
- Liqun Zou
- Número de teléfono: 18980601027
- Correo electrónico: Clinical_Zou@163.com
-
Chengdu, Porcelana
- Reclutamiento
- Sichuan Provincial People's Hospital
-
Contacto:
- Xiaobing Huang
- Número de teléfono: 18981838236
- Correo electrónico: hxb_trial@163.com
-
Investigador principal:
- Xiaobing Huang
-
Chongqing, Porcelana
- Reclutamiento
- The First Affiliated Hospital of Chongqing Medical University
-
Investigador principal:
- Xin Wang
-
Contacto:
- Xin Wang
- Correo electrónico: 925170788@qq.com
-
Chongqing, Porcelana
- Reclutamiento
- Chongqing University Cancer Hospital
-
Investigador principal:
- Yao Liu
-
Contacto:
- Yao Liu
- Correo electrónico: liuyao101709@163.com
-
Fujian, Porcelana
- Reclutamiento
- Quanzhou First Hospital.Fujian
-
Contacto:
- Xiongpeng Zhu
- Número de teléfono: 13805998581
- Correo electrónico: xiongpengzhu@163.com
-
Investigador principal:
- Xiongpeng Zhu
-
Fuzhou, Porcelana
- Reclutamiento
- Fujian Medical University Union Hospital
-
Investigador principal:
- Jianzhen Shen
-
Contacto:
- Jianzhen Shen
- Número de teléfono: 138 0955 2722
- Correo electrónico: doctorsjz@163.com
-
Guangzhou, Porcelana
- Reclutamiento
- Sun Yat-sen University Cancer Center
-
Investigador principal:
- Zhiming Li
-
Contacto:
- Zhiming Li
- Número de teléfono: 13719189172
- Correo electrónico: lzmsysu@163.com
-
Guangzhou, Porcelana
- Reclutamiento
- Guangdong Provincial People's Hospital
-
Contacto:
- Xiaojuan Wei
- Número de teléfono: 86 13560097145
- Correo electrónico: jxw919@hotmail.com
-
Investigador principal:
- Xiaojuan Wei
-
Guangzhou, Porcelana
- Reclutamiento
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
Investigador principal:
- Yuhua Li
-
Contacto:
- Yuhua Li
- Número de teléfono: 13533706656
- Correo electrónico: liyuhua2011gz@163.com
-
Guiyang, Porcelana
- Reclutamiento
- The Affiliated Hospital of Guizhou Medical University
-
Investigador principal:
- Yan Zhang
-
Contacto:
- Yan Zhang
- Número de teléfono: 86 18984155172
- Correo electrónico: Zhangyan20010802@sina.com
-
Hangzhou, Porcelana
- Reclutamiento
- Zhejiang Cancer Hospital
-
Investigador principal:
- Haiyan Yang
-
Contacto:
- Haiyan Yang
- Correo electrónico: 2054451461@qq.com
-
Hangzhou, Porcelana
- Reclutamiento
- The First Affiliated Hospital, Zhejiang University
-
Investigador principal:
- Zhen Cai
-
Contacto:
- Zhen Cai
- Número de teléfono: 13857190311
- Correo electrónico: czclinicaltrial@163.com
-
Harbin, Porcelana
- Reclutamiento
- Harbin Medical University Cancer Hospital
-
Contacto:
- Qingyuan Zhang
- Número de teléfono: 13313612989
- Correo electrónico: sy86298276@163.com
-
Investigador principal:
- Qingyuan Zhang
-
Hefei, Porcelana
- Reclutamiento
- The Second Affiliated Hospital of Anhui Medical University
-
Contacto:
- Zhimin Zhai
- Número de teléfono: 13855147434
- Correo electrónico: zzzm889@163.com
-
Investigador principal:
- Zhimin Zhai
-
Jinan, Porcelana
- Reclutamiento
- Qilu Hospital of Shandong University
-
Contacto:
- Shuqian Xu
- Número de teléfono: 18560087013
- Correo electrónico: yoyoshuqian@126.com
-
Investigador principal:
- Shuqian Xu
-
Jinan, Porcelana
- Reclutamiento
- Shandong Cancer Hospital & Institute
-
Investigador principal:
- Zengjun Li
-
Contacto:
- Zengjun Li
- Número de teléfono: 15735178591
- Correo electrónico: zengjunli@163.com
-
Kunming, Porcelana
- Aún no reclutando
- The First Affiliated Hospital of Kunming Medical University
-
Contacto:
- Mingxia Shi
- Número de teléfono: 86 138 8806 0581
- Correo electrónico: shmxia2002@sina.com
-
Investigador principal:
- Mingxia Shi
-
Nanchang, Porcelana
- Reclutamiento
- Jiangxi Cancer Hospital
-
Investigador principal:
- Yan Huang
-
Contacto:
- Yan Huang
- Correo electrónico: 29265061@qq.com
-
Nanjing, Porcelana
- Reclutamiento
- Jiangsu Cancer Hospital
-
Investigador principal:
- Yan Zhang
-
Contacto:
- Yan Zhang
- Número de teléfono: 13914712395
- Correo electrónico: zhangyan1106@njmu.edu.cn
-
Nanjing, Porcelana
- Reclutamiento
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
Contacto:
- Jingyan Xu
- Número de teléfono: 86 13951969610
- Correo electrónico: xjy1967@sina.com
-
Investigador principal:
- Jingyan Xu
-
Nanning, Porcelana
- Reclutamiento
- The First Affiliated Hospital of Guangxi Medical University
-
Investigador principal:
- Zhigang Peng
-
Contacto:
- Zhigang Peng
- Correo electrónico: 2557382235@qq.com
-
Qingdao, Porcelana
- Reclutamiento
- The Affiliated Hospital of Qingdao University
-
Contacto:
- Xia Zhao
- Número de teléfono: 18661803088
- Correo electrónico: Zhaoxia@qdu.edu.cn
-
Investigador principal:
- Xia Zhao
-
Shanghai, Porcelana
- Reclutamiento
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Investigador principal:
- Weili Zhao
-
Contacto:
- Weili Zhao
- Número de teléfono: 86 13512112076
- Correo electrónico: zwl_trial@163.com
-
Shanghai, Porcelana
- Reclutamiento
- Tongji Hospital of Tongji University
-
Contacto:
- Ping Li
- Número de teléfono: 13564181131
- Correo electrónico: lilyforever76@126.com
-
Investigador principal:
- Ping Li
-
Shanghai, Porcelana
- Aún no reclutando
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
Investigador principal:
- Ligen Liu
-
Contacto:
- Ligen Liu
- Número de teléfono: 86 18017337037
- Correo electrónico: llg3532@shtrhospital.com
-
Shenyang, Porcelana
- Reclutamiento
- Shengjing Hospital of China Medical University
-
Investigador principal:
- Wei Yang
-
Contacto:
- Wei Yang
- Número de teléfono: 18940251012
- Correo electrónico: sjyangw@163.com
-
Shenzhen, Porcelana
- Reclutamiento
- Shenzhen people's hospital
-
Investigador principal:
- Jihao Zhou
-
Contacto:
- Jihao Zhou
- Número de teléfono: 86 18718678693
- Correo electrónico: zhoujihao@aliyun.com
-
Taiyuan, Porcelana
- Reclutamiento
- Shanxi Provincial Cancer Hospital
-
Investigador principal:
- Liping Su
-
Contacto:
- Liping Su
- Número de teléfono: 13835158122
- Correo electrónico: slpsy2022@163.com
-
Tangshan, Porcelana
- Reclutamiento
- North China University of Science and Technology Affiliated Hospital
-
Contacto:
- Zhenyu Yan
- Número de teléfono: 15931508262
- Correo electrónico: hbyzy2011@163.com
-
Investigador principal:
- Zhenyu Yan
-
Tianjin, Porcelana
- Reclutamiento
- Tianjin Medical University Cancer Institute & Hospital
-
Investigador principal:
- Zhengzi Qian
-
Contacto:
- Zhengzi Qian
- Número de teléfono: 13702031222
- Correo electrónico: qzz@163.com
-
Tianjin, Porcelana
- Reclutamiento
- Tianjin People's Hospital
-
Contacto:
- Xingli Zhao
- Número de teléfono: 13752255454
- Correo electrónico: insectzhao@163.com
-
Investigador principal:
- Xingli Zhao
-
Tianjin, Porcelana
- Reclutamiento
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
Investigador principal:
- Dehui Zou
-
Contacto:
- Dehui Zou
- Número de teléfono: 13602100955
- Correo electrónico: zoudehui@ihcams.ac.cn
-
Wenzhou, Porcelana
- Reclutamiento
- The First Affiliated Hospital of WMU
-
Contacto:
- Songfu Jiang
- Número de teléfono: 86 15305770033
- Correo electrónico: jiangsongfu@189.cn
-
Investigador principal:
- Songfu Jiang
-
Wuhan, Porcelana
- Reclutamiento
- Hubei Cancer Hospital
-
Investigador principal:
- Huijing Wu
-
Contacto:
- Huijing Wu
- Correo electrónico: 3269614878@qq.com
-
Wuhan, Porcelana
- Reclutamiento
- Wuhan Union Hospital of China
-
Investigador principal:
- Liling Zhang
-
Contacto:
- Liling Zhang
- Número de teléfono: 15871725926
- Correo electrónico: lily1228@sina.com
-
Xi'an, Porcelana
- Reclutamiento
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Investigador principal:
- Pengcheng He
-
Contacto:
- Pengcheng He
- Número de teléfono: 18991232609
- Correo electrónico: hepc_gcp@163.com
-
Xi'an, Porcelana
- Reclutamiento
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
Investigador principal:
- Jie Liu
-
Contacto:
- Jie Liu
- Número de teléfono: 86 18092662371
- Correo electrónico: lieujie@163.com
-
Xiamen, Porcelana
- Aún no reclutando
- The First Affiliated Hospital of Xiamen University
-
Investigador principal:
- Bing Xu
-
Contacto:
- Bing Xu
- Número de teléfono: 86 18750918842
- Correo electrónico: xubingzhangjian@126.com
-
Xuzhou, Porcelana
- Reclutamiento
- The Affiliated Hospital of Xuzhou Medical University
-
Contacto:
- Wei Sang
- Número de teléfono: 86 13645207648
- Correo electrónico: 13645207648@126.com
-
Investigador principal:
- Wei Sang
-
Zhengzhou, Porcelana
- Reclutamiento
- Henan Cancer Hospital
-
Investigador principal:
- Keshu Zhou
-
Contacto:
- Keshu Zhou
- Número de teléfono: 13674902391
- Correo electrónico: dr_zkshu23810@163.com
-
Zhengzhou, Porcelana
- Reclutamiento
- The First Affiliated Hospital of Zhengzhou University
-
Contacto:
- Xudong Zhang
- Número de teléfono: 13633825183
- Correo electrónico: feverxxd@126.com
-
Investigador principal:
- Xudong Zhang
-
Ürümqi, Porcelana
- Reclutamiento
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Investigador principal:
- Yan Li
-
Contacto:
- Yan Li
- Número de teléfono: 86 13639935315
- Correo electrónico: liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana
- Reclutamiento
- Fudan University Shanghai Cancer Center
-
Contacto:
- Fangfang Lv
- Número de teléfono: 18017312613
- Correo electrónico: Lvff80@163.com
-
Investigador principal:
- Fangfang Lv
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Otros nombres:
|
|
Comparador de placebos: The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Otros nombres:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free survival (PFS)
Periodo de tiempo: Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
Periodo de tiempo: Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
Periodo de tiempo: Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
Periodo de tiempo: Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
Periodo de tiempo: Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
Periodo de tiempo: Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
Periodo de tiempo: Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
Periodo de tiempo: Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
Periodo de tiempo: Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
Periodo de tiempo: Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
Periodo de tiempo: Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
Periodo de tiempo: Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
Periodo de tiempo: Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Periodo de tiempo: At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Biomarker assessment
Periodo de tiempo: Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Periodo de tiempo: Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Weili Zhao, Ruijin Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma de células B
- Linfoma
- Enfermedades hemic y linfáticas
- Linfoma de células B grandes, difuso
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Terapéutica
- Rutas de administración de drogas
- Terapia con drogas
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Complejos de coordinación
- Desoxicitidina
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Anticuerpos, monoclonales, derivados de murino
- Oxaliplatino
- Rituximab
- Gemcitabina
- Inyecciones
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2025-760-00CH1
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .